.Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B02B_VitaminKAndOtherHemostatics.B02BD14_SusoctocogAlfa.SusoctocogAlfa .Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B02B_VitaminKAndOtherHemostatics.B02BD14_SusoctocogAlfa.SusoctocogAlfa| name: | SusoctocogAlfa | |
| ATC code: | B02BD14 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 200 | mg |
| volume of distribution: | 0.046 | L |
| clearance: | 2.8 | mL/h/kg |
| other parameters in model implementation | ||
Susoctocog alfa is a recombinant, factor VIII (FVIII) replacement therapy derived from human cell-line, used for the treatment and prevention of bleeding episodes and perioperative management in patients with congenital hemophilia A who have developed inhibitors to FVIII. It is used as a bypassing agent and is currently approved for clinical use in this indication.
Pharmacokinetic parameters for susoctocog alfa are reported in adult hemophilia A patients with FVIII inhibitors.